Blood Spot Thyroids + Dried Urine GCMS Estrogen Hormone Metabolites

Thyroid-stimulating hormone is the anterior pituitary glycoprotein that regulates thyroid follicular cell activity and thyroid hormone synthesis. TSH secretion is pulsatile and governed by negative feedback from free T4 and T3. Dried blood spot measurement captures the integrated concentration at the moment of collection, and correlation with venous serum is well established for screening purposes, though absolute values may differ slightly by platform.

TSH is the first-line test of thyroid function, with elevation signalling primary hypothyroidism and suppression indicating hyperthyroidism or excessive thyroid hormone replacement. In this panel TSH provides the thyroid-pituitary axis context for the concurrent oestrogen-metabolite profile, since thyroid dysfunction influences sex-hormone metabolism and menstrual regularity.

Free thyroxine is the unbound, biologically available fraction of T4, the principal secretory product of the thyroid gland. It circulates at picomolar concentrations, is distributed across compartments by equilibrium dialysis or immunoassay estimate, and serves as the substrate for peripheral deiodinase conversion to the more potent T3.

Free T4 distinguishes primary thyroid failure from secondary (pituitary) causes when TSH is abnormal, and monitors the adequacy of levothyroxine replacement. In this combined panel fT4 helps identify subclinical thyroid states that may alter hepatic phase I and phase II metabolism of oestrogens.

Free triiodothyronine is the unbound fraction of T3, the most potent thyroid hormone at the nuclear receptor. The majority of circulating T3 arises from peripheral 5'-deiodination of T4 rather than direct thyroid secretion, so fT3 reflects both thyroid output and extrathyroidal conversion capacity.

Free T3 is useful when T3 toxicosis is suspected, to assess peripheral conversion in treated hypothyroidism, and to screen for non-thyroidal illness that blunts T4-to-T3 conversion. In the context of oestrogen-metabolite assessment, fT3 provides a window into metabolic rate and hepatic enzymatic activity.

Thyroid peroxidase antibodies target the microsomal enzyme responsible for iodine organification and thyroid hormone synthesis. They are the hallmark of autoimmune thyroiditis (Hashimoto disease) and persist over years, though titre does not reliably predict progression to overt hypothyroidism.

Positive TPOAb confirms autoimmune aetiology in hypothyroidism, stratifies risk in subclinical disease, and may influence reproductive and obstetric management. In a thyroid-plus-oestrogen panel, TPOAb identifies patients whose thyroid dysfunction may fluctuate and whose immune dysregulation can affect sex-steroid pathways.

Estrone is the predominant oestrogen in postmenopausal women and arises from ovarian secretion, peripheral aromatisation of androstenedione in adipose tissue, and interconversion with estradiol. Urinary excretion of conjugated estrone and its glucuronide/sulphate conjugates reflects integrated 24-hour production when normalised to creatinine.

Estrone measurement in dried urine by gas chromatography–mass spectrometry (GCMS) offers a non-invasive snapshot of total oestrogen load. It is the parent oestrogen whose hydroxylation yields the 2-, 4-, and 16-pathway metabolites that are simultaneously quantified in this panel.

Estradiol is the most potent endogenous oestrogen, secreted principally by the ovarian granulosa cells in premenopausal women and by peripheral conversion in postmenopause. Urinary estradiol conjugates are excreted over 24 hours, and GCMS quantification avoids the cross-reactivity seen with immunoassay.

Dried-urine E2 complements serum measurement by integrating secretory pulses and reflecting tissue exposure over the collection window. It serves as the second parent oestrogen in the metabolic cascade and is interpreted alongside E1 and the hydroxylated metabolites.

Estriol is a weak oestrogen produced in small amounts by non-pregnant women via 16α-hydroxylation of estrone and estradiol. It is the dominant oestrogen of pregnancy, synthesised by the foetoplacental unit, but contributes minimally to oestrogenic activity in non-gravid states.

Urinary estriol in non-pregnant women is included for completeness in oestrogen profiling and can be elevated in some liver or adrenal conditions. It is a minor component of the total oestrogen–metabolite picture.

2-Hydroxyestrone is formed by CYP1A1/1A2-mediated hydroxylation of estrone at the C-2 position. It is considered a 'favourable' or less proliferative metabolite because it has weak oestrogenic activity, is rapidly conjugated, and does not form stable DNA adducts.

The 2-hydroxylation pathway is the quantitatively dominant route of oestrogen metabolism. Practitioners in functional and integrative medicine use the 2-OHE1 level and the 2:16α ratio as markers of detoxification capacity and, speculatively, as indicators of breast and endometrial cancer risk, though prospective validation in intervention trials is limited.

2-Hydroxyestradiol is the 2-hydroxylated metabolite of estradiol, formed by the same CYP1A enzymes. It mirrors the favourable metabolic profile of 2-OHE1 and is excreted as glucuronide and sulphate conjugates.

2-OHE2 contributes to the total 2-pathway flux and is summed with 2-OHE1 for ratio calculations. Its measurement adds granularity to the oestrogen-metabolite profile.

4-Hydroxyestrone is generated by CYP1B1 hydroxylation at the C-4 position. It retains oestrogenic activity and, unlike 2-hydroxy metabolites, can undergo redox cycling to form semiquinones and quinones that react with DNA to produce depurinating adducts.

Elevated 4-OHE1 has been associated in mechanistic studies with increased oxidative DNA damage and is hypothesised to contribute to oestrogen-related carcinogenesis. Some practitioners use the 4:2 hydroxy ratio as a marker of 'unfavourable' metabolism, though clinical outcome data linking ratios to cancer incidence remain inconclusive.

4-Hydroxyestradiol is the 4-hydroxylated derivative of estradiol and shares the potentially genotoxic redox profile of 4-OHE1. It is present at lower concentrations than the estrone metabolites.

4-OHE2 is measured to complete the 4-hydroxylation picture and is summed with 4-OHE1 when calculating pathway ratios. Its redox potential makes it a marker of interest in oxidative-stress and cancer-risk models.

16α-Hydroxyestrone is formed by CYP3A4-mediated hydroxylation at C-16. It is a potent oestrogen that binds covalently to the oestrogen receptor, creating a long-lived receptor–ligand complex that drives sustained transcriptional activity and cellular proliferation.

16α-OHE1 has been studied as a biomarker of proliferative oestrogenic activity and potential breast cancer risk. A low 2:16α ratio is often flagged in functional practice as indicating 'unfavourable' metabolism, though epidemiological studies have yielded mixed results and ratio-based interventions lack definitive outcome trials.

2-Methoxyestrone is formed by catechol-O-methyltransferase (COMT) methylation of 2-hydroxyestrone. Methylation stabilises the catechol, prevents redox cycling, and facilitates renal excretion, representing a protective conjugation step.

The ratio of methylated to unmethylated 2-hydroxy metabolites is used as an index of COMT activity and phase II detoxification capacity. Low methylation may indicate COMT polymorphisms, nutrient deficiencies (SAMe, B vitamins), or high oxidative burden.

2-Methoxyestradiol is the COMT-methylated product of 2-hydroxyestradiol. Beyond its role as a detoxified metabolite, 2-MeOE2 has been studied for anti-angiogenic and anti-proliferative properties in preclinical cancer models.

2-MeOE2 contributes to the aggregate methylation picture and is a marker of successful phase II conjugation. Its presence indicates functional COMT activity.

4-Methoxyestrone is the COMT-methylated derivative of 4-hydroxyestrone. Methylation of 4-hydroxy catechols is critical because it blocks the redox cycling and quinone formation that can damage DNA.

The 4-MeOE1 level and its ratio to unmethylated 4-OHE1 reflect the efficiency of phase II detoxification of the genotoxic 4-pathway. Low methylation in the presence of elevated 4-hydroxy metabolites is flagged as a potential risk marker.

4-Methoxyestradiol is the methylated product of 4-hydroxyestradiol, completing the 4-pathway detoxification cascade.

4-MeOE2 is measured to assess the completeness of 4-hydroxy metabolite clearance and is interpreted alongside 4-MeOE1 in the aggregate methylation picture.

This derived ratio compares the 2-hydroxylation pathway (considered less oestrogenic and non-genotoxic) with the 16α-hydroxylation pathway (more oestrogenic and proliferative). It is influenced by CYP1A and CYP3A activity, diet, body composition, and genetic polymorphisms.

A higher 2:16α ratio is hypothesised to indicate favourable oestrogen metabolism and lower proliferative drive, and has been explored as a modifiable biomarker in breast cancer risk reduction. Dietary indole-3-carbinol, cruciferous vegetables, and lifestyle interventions have been shown to shift the ratio, though definitive clinical outcome data are lacking.